ArticleAntimicrobial agents and chemotherapy2014
Triazole-based compound as a candidate to develop novel medicines to treat toxoplasmosis.
Article in Antimicrobial agents and chemotherapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Nanoformulation-Based 1,2,3-Triazole Sulfonamides for Anti-Tropical medicine and infectious disease · 2023Article
- Inhibition ofJournal of enzyme inhibition and medicinal chemistry · 2022Article
- Synthesis and anti-Annals of medicine and surgery (2012) · 2022Article
- In vitro anti-Toxoplasma gondii efficacy of synthesised benzyltriazole derivatives.The Onderstepoort journal of veterinary research · 2021Article
- Article
- Docking and QSAR of Aminothioureas at the SARS-CoV-2 S-Protein-Human ACE2 Receptor Interface.Molecules (Basel, Switzerland) · 2020Article
- Imidazole derivatives as antiparasitic agents and use of molecular modeling to investigate the structure-activity relationship.Parasitology research · 2020Article
- Synthesis and biological evaluation of ursolic acid derivatives bearing triazole moieties as potential anti-Toxoplasma gondii agents.Journal of enzyme inhibition and medicinal chemistry · 2019Article
- Drugs in development for toxoplasmosis: advances, challenges, and current status.Drug design, development and therapy · 2017Review
- A Systematic Review ofFrontiers in microbiology · 2017Review
- Characterization of Toxoplasma gondii glyoxalase 1 and evaluation of inhibitory effects of curcumin on the enzyme and parasite cultures.Parasites & vectors · 2015Article
- Phytoecdysteroids as modulators of the Toxoplasma gondii growth rate in human and mouse cells.Parasites & vectors · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This article reports anti-Toxoplasma gondii activity of 3-(thiophen-2-yl)-1,2,4-triazole-5-thione. The compound displayed significant and reproducible antiparasitic effects at nontoxic concentrations for the host cells, with an experimentally determined 50% inhibitory concentration (IC50) at least 30 times better than that of the known chemotherapeutic agent sulfadiazine. Purine nucleoside phosphorylase was defined as the probable target for anti-Toxoplasma activity of the tested compound. These results provide the foundation for future work to develop a new class of medicines to better treat toxoplasmosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.